Business Context and Reporting Period
This Form 8-K Current Report was filed by Dandrit Biotech USA, Inc. (noted as Lunai Bioworks Inc. in metadata) on July 11, 2017. The registrant is a Delaware corporation with principal executive offices in Copenhagen, Denmark. The report details a completed private placement offering and a key executive appointment.
Key Financial Metrics and Capital Structure
- Capital Raised: The Company sold 1,231,561 Units for total proceeds of $1,601,029.30.
- Unit Composition: Each Unit consisted of one share of Common Stock and one Warrant to purchase two shares of Common Stock.
- Pricing: Units were sold at $1.30 per Unit; Warrants have a strike price of $1.30 per share.
- Share Count:
- Prior to closing: 12,433,290 shares issued and outstanding.
- Shares issued in offering: 1,231,561 shares (representing 9.91% of pre-offering outstanding shares).
- Post-closing total: 13,664,851 shares issued and outstanding.
- Warrant Terms: Warrants are freely exercisable until the fifth anniversary of issuance.
- Underwriting: No underwriter or placement agent was engaged; the offering was conducted directly by the Company under Regulation S.
Material Changes
The primary material change reported is the increase in outstanding common stock by approximately 9.91% due to the private placement closing on July 12, 2017. Additionally, the Company's leadership structure changed with the appointment of a new Chief Financial Officer.
Management Commentary and Corporate Actions
- Executive Appointment: On July 11, 2017, the Company appointed Robert Wolfe as Chief Financial Officer, effective immediately.
- Background: Mr. Wolfe previously served as CFO and director of the Company from January 2014 to April 2015. He has extensive experience as Chairman, CEO, and CFO of Advanced Oxygen Technologies Inc. since 1997.
- Compensation: The filing states there are no arrangements or understandings regarding his appointment that require disclosure under Item 404(a) of Regulation S-K.
- Outlook/Guidance: The filing text does not provide specific financial guidance, revenue outlook, or management commentary on future operational performance.
- Risks/Contingencies: The filing notes that investors are not "U.S. persons" as defined by Regulation S. No specific litigation or contingent liabilities are detailed in this report.
Investor Verification Checklist
- Verify the exact number of shares outstanding post-offering (13,664,851) against subsequent filings to confirm no further dilution.
- Review the full text of the Subscription Agreement (Exhibit 10.1) and Warrant Agreement (Exhibit 10.2) referenced in the filing for restrictive covenants or specific exercise conditions.
- Confirm the utilization of the $1.6 million in proceeds, as the filing does not specify the intended use of funds.
- Monitor the Company's cash position and burn rate, as this filing does not provide current liquidity metrics or operating expenses.
- Check for any subsequent filings regarding the performance or tenure of the newly appointed CFO, Robert Wolfe.